Drug Trial Radar · NCT07286058
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,182
Planned (sponsor's estimate)
Start
Mar 11, 2026
Primary completion
Dec 18, 2029
Study completion Dec 18, 2029
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD). Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.
Conditions
- Psoriatic Arthritis
Interventions
ZasocitinibDrug
Zasocitinib oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From start of study drug administration up to follow-up (up to Week 108)
- Number of Participants With Adverse Events of Special Interest (AESI)Time frame: From start of study drug administration up to follow-up (up to Week 108)
- Number of Participants With Clinically Significant Changes in Vital Sign ValuesTime frame: From start of study drug administration up to follow-up (up to Week 108)
- Number of Participants With Clinically Significant Changes in Clinical Laboratory ValuesTime frame: From start of study drug administration up to follow-up (up to Week 108)
Locations
111 sites in 20 countries. Site status is shown where the registry gives one.
Jeffrey Loomer, MD Arizona Arthritis & Rheumatology Research
Tucson, Arizona · Recruiting
First OC Dermatology Research Inc.
Fountain Valley, California · Recruiting
Purushotham & Akther Kotha MD
La Mesa, California · Recruiting
Triwest Research Associates LLC
La Mesa, California · Recruiting
The Cohen Medical Centers
Thousand Oaks, California · Recruiting
Denver Arthritis Clinic - Lowry
Denver, Colorado · Recruiting
Direct Helpers Research Center
Hialeah, Florida · Recruiting
Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research
Hialeah, Florida · Recruiting
Bioresearch Partners
Miami, Florida · Recruiting
IRIS Research and Development
Plantation, Florida · Recruiting
Clinical Research of West Florida | Tampa
Tampa, Florida · Recruiting
Klein and Associates, M.D., P.A.
Hagerstown, Maryland · Recruiting
Michigan Rheumatology Group, P.C. - Grand Blanc Office
Grand Blanc, Michigan · Recruiting
DJL Clinical Research
Charlotte, North Carolina · Recruiting
Paramount Medical Research & Consulting, LLC
Middleburg Heights, Ohio · Recruiting
West Tennessee Research Institute
Jackson, Tennessee · Recruiting
Accurate Clinical Research
Baytown, Texas · Recruiting
Novel Research LLC
Bellaire, Texas · Recruiting
Novel Research | Abigail Neiman - Houston, TX
Houston, Texas · Recruiting
Northwest Houston Arthritis Center
Houston, Texas · Recruiting
West Texas Clinical Research
Lubbock, Texas · Recruiting
Southwest Rheumatology Research, LLC
Mesquite, Texas · Recruiting
Advanced Rheumatology of Houston
The Woodlands, Texas · Recruiting
Centro de Investigaciones Reumatologicas
San Miguel de Tucumán, Argentina · Recruiting
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia · Recruiting
R.K. Will Pty Ltd
Victoria Park, Western Australia, Australia · Recruiting
El Centro de Estudios Reumatologicos (CER)
Providencia, Chile · Recruiting
Estudios Clinicos CTR
Santiago, Chile · Recruiting
Clinica Dermacross S.A.
Santiago, Chile · Recruiting
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Chengdu, China · Recruiting
The First Affiliated Hospital Of Bengbu Medical College
Bengbu, Anhui, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Guangzhou First People's Hospital
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen University - The Third Affiliated Hospital
Guangzhou, Guangdong, China · Recruiting
Shenzhen People's Hospital
Shenzhen, Guangdong, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Recruiting
Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)
Wuhan, Hubei, China · Recruiting
Central South University - Xiangya School of Medicine - Zhuzhou Central Hospital
Zhuzhou, Hunan, China · Recruiting
The First Affiliated Hospital of Baotou Medical College
Baotou Shi, Inner Mongolia, China · Recruiting
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.